iwNHL 2019 e-learning

View iwNHL 2019 webcasts now!

The 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL) took place on September 6–8, 2019, in Boston, MA.

Leading experts in the field came together to discuss the hot topics in NHL, including T-cell lymphomas, tumor microenvironment, immunotherapy, novel targets & agents, cellular therapy, in addition to a special lecture by Elaine Jaffe celebrating 25 years of the REAL classification.

These webcasts will provide insight into these key themes and will help you consolidate your knowledge of NHL. To view each presentation simply click on its title. Please note that presentations from Session III are not available due to unpublished data.

Session I: T-cell Lymphomas

▶ Defining vulnerabilities and new targets in T-cell lymphomas
David Weinstock

▶ 25 years after REAL: looking back and looking forward
Elaine Jaffe

Session II: the Tumor Microenvironment in Lymphoma

▶ Genetics of follicular lymphoma and their impact on the tumor microenvironment
Robert Kridel

▶ Optimizing checkpoint inhibitors for lymphoma
Andrew Zelenetz

▶ The dual SYK/JAK inhibitor cerdulatinib: update 2019
Ryan Wilcox

Session IV: T-Cell Therapies for Lymphoma – CD19-CARs and Beyond

▶ CD19-specific CAR T-cells for NHL: an overview
David Maloney

▶ CD20-targeted CAR T-cell therapy for lymphoma
Brian Till

▶ Developing and evaluating CAR T-cells for T-cell lymphoma
Max Mamonkin

Session V: Novel Lymphoma Targets/Agents

▶ Venetoclax combinations in DLBCL
Sven de Vos

▶ Immunomodulatory drugs – where are we going?
Thomas Witzig

▶ Ibrutinib combinations for DLBCL
Francisco Hernandez-Ilizaliturri

▶ Zanubrutinib: a highly targeted Bruton tyrosine kinase inhibitor
Andrew Zelenetz

▶ Acalabrutinib
Thomas Witzig

▶ Oral PI3K-δ and PI3K-γ inhibitors in lymphoma
Sven de Vos 

Session VI: Immunotherapy of Lymphoma

▶ Checkpoint inhibitors in NHL
Kerry Savage 

 

Explore More Lymphoma Content on VJHemOnc

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals